[ad_1] An experimental drug for Alzheimer’s disease from Eisai and Biogen slowed cognitive decline in a closely watched trial, but may carry a risk of dangerous side effects for certain patients, according to new data presented on Tuesday. The drug, lecanemab, was associated with a type of brain swelling in 12.6 per cent of trial patients, a side effect previously seen with similar drugs. Fourteen per cent of patients had microhemorrhages in the brain —…
"Alzheimer’s drug slowed cognitive decline overall in trial, but with major side effects for some"
General News Blog